Objective: To perform a systematic review to determine the incidence of VAP and its attributable mortality rate, length of stay, and costs.
V entilator-associated pneumonia (VAP) is the most frequent nosocomial infection in the intensive care unit (ICU) (1) (2) (3) (4) (5) (6) . Several studies report that patients with VAP have an increased length of stay and hospital costs (7, 8) ; some studies have even found mortality attributable to VAP (9) . The literature also suggests that late-onset VAP (variably defined as VAP developing 48 -96 hrs after the onset of mechanical ventilation) is usually caused by more pathogenic organisms compared with early-onset VAP and thus leads to even greater morbidity and mortality rates (10 -15) . Unfortunately, studies of patients with VAP have often provided contradictory results, making it challenging to provide an overall estimate of the clinical and economic consequences of VAP.
We thus undertook a quantitative systematic review to answer the following questions: What is the incidence of VAP in mechanically ventilated patients? What is the attributable mortality of VAP? What is the prolongation of ICU stay attributable to VAP? What are the attributable costs of VAP?
Although recent reviews on the epidemiology of VAP have been published, none has used a systematic approach to quantitatively combine the results of available studies to provide a summary measure of the incidence and impact of VAP (16 -24) . A systematic approach is essential to identify all relevant studies and appropriately synthesize the literature; the use of a priori explicitly stated inclusion criteria minimizes bias.
METHODS
Search Strategy. We performed a computerized search of PUBMED (including MED-LINE), Current Contents, CINAHL, and the Cochrane Network using the following keywords: ventilator-associated pneumonia, prevention, prospective cohort, nosocomial pneumonia, outcomes, mortality, cost, and various combinations of these search terms. The end date of the search was March 1, 2004 . The search was conducted by one author (NS). Reference lists of articles were searched to identify additional articles.
As the management of mechanically ventilated patients in the ICU has changed substantially over the past two decades, we chose to include only those studies published after 1990. To be included, articles had to satisfy specific criteria depending on the outcome (e.g., VAP incidence, attributable mortality).
For calculating the incidence of VAP, we included observational studies or randomized controlled trials that provided adequate data to obtain the incidence of VAP (i.e., number of patients who were mechanically ventilated and the proportion who developed VAP). For calculating the incidence of VAP from randomized controlled trials that compared an intervention with control, we used only data provided from the control arm. The incidence of VAP was calculated separately for cohort studies and the control arm of randomized trials.
For assessing mortality and length of stay related to VAP, we included studies reporting outcome data of VAP (e.g., mortality, length of ICU stay) only if they were matched cohort studies and if data were provided on the crude mortality in both the exposed and nonexposed group.
Data were extracted by one author (NS) using a standardized form for each relevant study and included the total number of mechanically ventilated patients, the proportion with VAP, the patient population evaluated, diagnostic criteria used for VAP, and, if provided, stratification of the incidence of VAP by duration of mechanical ventilation. Data on the length of stay, cost, and mortality attributable to VAP were also extracted. No formal assessment of validity of studies was performed, beyond the application of our inclusion criteria to all studies extracted. For assessment of incidence of VAP, all included studies provided the data necessary to determine incidence, using either a clinical or an invasive diagnostic criterion for VAP. For assessment of outcomes related to VAP, only matched cohort studies were included, all of which used similar methodology.
Statistical Analysis. The cumulative incidence of VAP was calculated by combining the results of several studies using standard formulas for combining proportions, in which the weighted average and variance are calculated (25). Results from studies comparing ICU and hospital mortality due to VAP, additional length of stay, and additional days of mechanical ventilation were pooled using a random effects model, with assessment of heterogeneity (26). Statistical analyses were done using SAS software (version 8.2, Cary, NC) and StatsDirect (2002, UK).
Calculation of Costs. The economic estimates were derived using microcosting techniques (27, 28), with costs from the University of Wisconsin Medical Center serving as a reference. Estimates for cost related to length of stay were based on literature review and expert opinion. Antimicrobial costs were estimated using the average wholesale price from the Pharmacy Red Book (2003) . Physician and other health care personnel charges and indirect costs, such as lost days from work and disability associated with VAP, were not included in our cost calculations.
RESULTS
Incidence of VAP. Eighty-nine studies were identified that assessed the risk of VAP in patients receiving mechanical ventilation (7-9, 29 -50, 51-114) . These studies were of two types: prospective cohort studies or nonrandomized quasiexperimental trials and randomized controlled trials. They will be discussed separately. Importantly, most of the published studies assessing the incidence of VAP excluded patients who received mechanical ventilation for Ͻ48 hrs.
Thirty-eight prospective cohort or nonrandomized studies encompassing 48,112 patients were identified (Table 1) (7-9, 29 -57, 106 -111) . Overall, the pooled cumulative incidence of developing VAP in patients receiving mechanical ventilation was 9.7% (95% confidence interval [CI], 7.0 -12.5). The incidence of VAP in medical-surgical patients (24 studies) and medical ICUs alone (six studies) was 9.1% (95% CI, 5.9 -12.3%) and 17.0% (5.9 -28.0%) respectively.
Fifty-one prospective randomized trials encompassing 4,802 patients in the comparator arms were retrieved ( Table 2 ) (58 -105, 112-114) . Overall, the pooled cumulative incidence of developing VAP in patients receiving mechanical ventilation was 22.8% (95% CI, 18.8 -26.9%).
Mortality and Length of Stay Attributable to VAP. We identified eight matched cohort studies encompassing nine reports on the attributable mortality of VAP (8, 9, 42, 108, (115) (116) (117) (Table 3) . Matching criteria varied widely among studies; most, however, matched by severity of illness using the Simplified Acute Physiology Score, Acute Physiology and Chronic Health Evaluation, or Abbreviated Injury Scale score. Seven studies were performed in patients in medicalsurgical or medical ICUs. Five studies used protected specimen brush/bronchoalveolar lavage for diagnosis of VAP (8, 9, 42, 108, 116) . Six studies used ICU mortality as an outcome (8, 9, 42, 108, (115) (116) (117) ; three measured hospital mortality as the outcome. Length of stay in the ICU was measured by five studies (8, 9, 42, 116, 117) , and five also evaluated hospital length of stay. Only three studies reported data on additional length of mechanical ventilation due to VAP.
Of the nine reports, four failed to find a statistically significant attributable mortality of VAP (8, 42, 45, 108) ; the remainder reported an excess mortality that varied between approximately 15% and 50% in cases compared with controls (115, 116, 117, 9) . The summary estimate (odds ratio) for ICU mortality in the six studies in which it was reported was 2.03 (95% CI, 1.16 -3.56); however, significant statistical heterogeneity was found (p ϭ .05).
Pooled results from the four studies that evaluated mortality during the entire duration of hospitalization showed an odds ratio of 1.64 (95% CI, 0.86 -3.14) (42, 45, 115) .
Pooled results for ICU length of stay (LOS) showed that VAP was associated with a mean ICU LOS of 6.10 additional days (95% CI, 5.32-6.87). Although no statistically significant heterogeneity was found, only three studies provided sufficient data to calculate a pooled LOS (42, 45, 117) .
Attributable VAP Costs. Our pooled estimate from the literature indicated that the increased length of ICU stay due to VAP ranges from 5 to 7 days. Using the low range of this estimate as the attributable LOS, we then added the costs of the diagnostic tests and the cost of treatment (piperacillin-tazobactam, ciprofloxacin, and vancomycin) to derive the direct cost of VAP. The additional cost of evaluating and treating a patient with VAP using noninvasive diagnostic meth-ods and a typical antibiotic regimen for eight days of treatment at the University of Wisconsin would be $10,019 (Table 4 ). If we use the upper limit of LOS (i.e., 7 days), attributable VAP cost is estimated to be $13,647.
DISCUSSION
Our review indicates that VAP is a common hospital-associated infection, occurring in between 10% and 20% of patients receiving mechanical ventilation for Ͼ48 hrs. The difference in incidence found among cohort and randomized trials is likely due to differing criteria for inclusion in these two types of studies. Most cohort studies we reviewed included consecutive ICU admissions (some of whom were probably at low risk for VAP), whereas the randomized trials included primarily those at higher risk of developing VAP.
Our results also suggest a likely twofold increase in ICU mortality attributable to VAP; however, this result should be viewed cautiously as significant statistical heterogeneity was found.
Although crude ICU mortality rates of 16 -76% have been reported for VAP in a number of studies (7, 11, 41, 54, 108, 118) , the extent of mortality attributable to VAP (and, therefore, modifiable by the prevention of VAP) is unclear. Some studies have reported risk ratios for mortality in patients with VAP compared with those without VAP of 2.2-4.4 (9, 115, 116) , but others have failed to find a statistically significant increased risk (8, 45, 108) . This discrepancy may be partially explained by the inclusion of different patient populations across studies with varying baseline risks for death (119) . Second, methodological differences among the individual stud-ies also likely contribute to this discordance. Specifically, the choice of matching variables in the case of matched studies (Table 3 ) and the use of covariates for adjustment in the case of unmatched cohort studies could lead to differing results. Third, variation in the diagnostic criteria for VAP used in individual studies may result in varying attributable mortality rates. Finally, variations in institutional microbiology (particularly the presence of pathogens resistant to multiple antimicrobials) (31) and relative prolongation of the duration of mechanical ventilation may account for increased attributable mortality (29).
The results of unmatched cohort studies using multivariable analyses conducted to evaluate the independent role played by VAP in causing death have been conflicting. In a study by Craven et al. (120) , the investigators compared medical and surgical ICU patients with regard to mortality from nosocomial pneumonia; most patients in both groups were receiving mechanical ventilation. Overall, patients in the medical ICU had a higher fatality rate than patients in the surgical ICU (18% vs. 10%, p Ͻ .0001); however, the mortality rate from nosocomial infection was not significantly different (8.0% vs. 6.0%). In contrast, stepwise logistic regression analysis in another study demonstrated that ICU-acquired pneumonia significantly increased the risk of death (odds ratio, 1.91; 95% CI, 1.6 -2.3); however, not all patients in this study were receiving mechanical ventilation (121) . In a study of 1,118 patients receiving mechanical ventilation, Fagon et al. (122) found that VAP was associated with a one and half-fold increased risk of death (odds ratio, 1.51; 95% CI, 1.11-2.03), after adjusting for severity of illness, presence of organ dysfunction, and underlying disease. However, the microbial etiology and the treatment of VAP were not reported.
Data on the financial impact of VAP are limited. Comparison of costs across studies is difficult for several reasons. First, the methodology for calculating costs varies. Many studies have relied on hospital charges rather than true costs (45, 108) , thereby overestimating the actual cost of VAP. In a retrospective casecontrol study of trauma patients, Baker et al. (108) found that hospital charges in- Additionally, studies vary in their inclusion criteria for costs relevant to VAP. Papazian et al. (42) reported a $7,752 additional cost of VAP in 1996; however, only ICU stay was included in calculation of costs. In a recent prospective cohort study of 819 mechanically ventilated patients, 127 of whom developed VAP, Warren et al. (7) found that VAP was associated with attributable costs of $11,897 (95% CI, $5,265-$26,214) in 2003 in a large suburban nonteaching hospital.
Microcosting is a method used to capture costs associated with patterns of resource use. Shorr and O'Malley (123) estimated the costs associated with VAP in 2001 to be $5,365, using microcosting that included the cost of excess ICU length of stay, diagnostic tests, and therapeutic antibiotics directed toward treat-ing VAP. Using a similar technique, our study found that an episode of VAP has attributable costs of Ն$10,019 (124) .
Our review has several limitations. We restricted our search to studies published since 1990. This was done because the management and epidemiology of VAP have changed considerably over time. Although we believe that the inclusion of earlier studies would have limited the applicability of our results to today's VAP population, it is possible that the exclusion of earlier studies affected the accuracy of our results. We also only included English language studies in our analysis. However, because of the large number of studies identified, we believe that our point estimates and confidence intervals accurately reflect the incidence and impact of VAP. Finally, since physician charges were not included in calculation of costs, our estimate of the financial impact of VAP is conservative.
CONCLUSIONS
We found that VAP is a common hospital-associated infection with a clear impact on length of stay and hospital costs and a potentially substantial attributable mortality rate. The results of our analysis can be used by clinicians, policymakers, patient safety officers, and infection control personnel to better allocate resources for prevention of nosocomial infection. We also hope our results will be of use to investigators planning to evaluate the cost-effectiveness of various strategies for preventing VAP.
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